Description: Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.
Home Page: www.elicera.com
World Trade Center GOeteborg
Gothenburg,
412 51
Sweden
Phone:
46 7 03 31 90 51
Officers
| Name | Title |
|---|---|
| Mr. Jamal El-Mosleh M.Sc. | CEO & Co-Founder |
| Prof. Magnus Essand | Chief Science Officer, Co-Founder & Director |
| Mr. Di Yu | Co-Founder and Head of Transitional Research & Technical Operations |
| Mr. Ingvar Karlsson | Chief Financial Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2101 |
| Price-to-Sales TTM: | 106.4825 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |